The rising cost of glaucoma drugs

British Journal of Ophthalmology

Volumn 90, Issue 2, 2006, Pages 130-131

  Azuara Blanco, Augusto ^a,c   Burr, J ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Eye Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; PROSTAGLANDIN DERIVATIVE;

COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GLAUCOMA; GLAUCOMA SURGERY; HEALTH CARE UTILIZATION; HUMAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TRABECULOPLASTY; TREATMENT INDICATION; VISUAL FIELD;

CARBONIC ANHYDRASE INHIBITORS; DRUG COSTS; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; LASER SURGERY; PROSTAGLANDINS; TRABECULECTOMY;

EID: 31544435455     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.079996     Document Type: Editorial

References (14)

1. Bateman DN, Clark R, Azuara-Blanco A, et al. The impact of new drugs on management of glaucoma in Scotland: observational study. BMJ 2001;323:1401-2.
2. Baudouin C, Rouland JF, Le Pen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France, Eur J Ophthalmol 2003;13:S53-60.
3. Walland MJ. Glaucoma treatment in Australia: changing patterns of therapy 1994-2003. Clin Experiment Ophthalmol 2004;32:590-6.
4. De Natale R, Draghi E, Dorigo MT. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 2004;82:393-6.
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
6. Hyman LG, Komaroff E, Heijl A, et al. Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in the Early Manifest Glaucoma Trial. Ophthalmology 2005;112:1505-13.
7. Zhang WY, Po AL, Dua HS, et al. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-90.
8. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev 2005;18:CD004399.
9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995;120:718-31.
10. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial, Arch Ophthalmol 2003;121:48-56.
11. Harper R, Reeves B. Compliance with methodological standards when evaluating ophthalmic diagnostic tests. Invest Ophthalmol Vis Sci 1999;40:1650-7.
12. Siddiqui MA, Azuara-Blanco A, Burr J. The quality of reporting of diagnostic accuracy studies published in ophthalmic journals. Br J Ophthalmol 2005;89:261-5.
13. Tuulonen A. Is more always better? Acta Ophthalmol Scand 2004;82:377-9.
14. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003;110:726-33.